Home » Healthcare » Cell Therapy Market

Cell Therapy Market By Use Type (Clinical Use, Research Use); By Therapy Type (Autologous Therapies, Allogenic Therapies); By End User (Hospitals & Clinics, Academic & Research Institutes); By Technology (Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, Three-dimensional Technology); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4999

Published: | Report ID: 36722 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Cell Therapy Market Size 2024  USD 5291.58 Million
Cell Therapy Market, CAGR  13.31%
Cell Therapy Market Size 2032  USD 14379.09 Million

Market Overview

The Cell Therapy Market is projected to surge from USD 5291.58 million in 2024 to USD 14379.09 million by 2032, reflecting an impressive compound annual growth rate of 13.31%.

The Cell Therapy Market is driven by increasing prevalence of chronic diseases such as cancer and autoimmune disorders, coupled with growing investments in research and development activities. Advancements in biotechnology and genetic engineering have led to the development of innovative cell-based therapies, further propelling market growth. Moreover, favorable regulatory landscapes and rising adoption of personalized medicine are contributing to the expansion of the market. Additionally, the emergence of novel technologies like gene editing and stem cell engineering is poised to revolutionize the field of cell therapy, offering promising avenues for future growth and therapeutic breakthroughs.

Geographical analysis reveals diverse trends in the Cell Therapy Market, with North America dominating due to strong infrastructure, advanced healthcare facilities, and substantial investments in research and development. Europe follows closely, driven by supportive regulatory frameworks and a growing patient pool. Asia Pacific showcases rapid growth attributed to increasing healthcare expenditure and rising awareness about advanced treatment options. Key players in the market include Novartis AG, Gilead Sciences, Inc., and Bristol-Myers Squibb Company, among others, who are actively engaged in strategic collaborations, product launches, and acquisitions to strengthen their market presence and drive innovation in cell therapy technologies.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Drivers

Rising Prevalence of Chronic Diseases

An aging population and unhealthy lifestyles contribute to an increasing prevalence of chronic diseases like cancer, autoimmune disorders, and neurological conditions. For instance, by 2050, the number of people aged 60 years and older is expected to double to 2.1 billion. This demographic shift is accompanied by a rise in chronic diseases. In fact, about 23% of the global disease burden is among the aging population, with cardiovascular disease accounting for about 30.3% of the global disease burden among this group.

Advancements in Cell Engineering Technologies

Breakthroughs in cell engineering techniques like CAR T-cell therapy and CRISPR are enabling the modification and manipulation of cells to target specific diseases more effectively. For instance, CAR T-cell therapy has led to sustained remissions in populations of otherwise refractory patients and, more specifically, has demonstrated complete response rates of > 80–97% in certain B-cell malignancies such as acute lymphoblastic leukemia (ALL). Moreover, the application of CRISPR-Cas9 in CAR-T cell-based tumor immunotherapies is gaining traction. Over 80% complete remission was acquired in refractory or relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL) patients after CD19-CART cell treatment, and 85% complete remission was reached in ALL patients.

Growing Body of Clinical Trials and Positive Results

The number of clinical trials investigating the safety and efficacy of cell therapies is steadily increasing. For instance, as of April 2022, there are nearly 1,800 active cell therapy trials, a 33% increase from last year, compared to a 43% increase from 2020 to 2021 and 24% increase from 2019 to 2020. This trend indicates a growing interest and confidence in the potential of cell therapies. Positive results from these trials, particularly for previously untreatable conditions, boost investor confidence and market momentum.

Increasing Government Funding and Support

Government agencies around the world are increasing funding for cell therapy research and development. For instance, the American Society of Gene & Cell Therapy has set a goal to increase funding for gene and cell therapy research through NIH and ARPA-H. In India, the Department of Biotechnology and BIRAC have supported the first CAR-T cell therapy conducted at ACTREC, Tata Hospital in Mumbai, with a grant of 19.15 Cr crore for conducting a first-in-human phase-1/2 clinical trial of the CAR-T cells. This financial support accelerates clinical trials and facilitates broader access to these therapies, driving market expansion. According to data from ClinicalTrials.gov, as of April 2022, there are nearly 1,800 active cell therapy trials, a 33% increase from last year, compared to a 43% increase from 2020 to 2021 and 24% increase from 2019 to 2020.

Market Trends

Advancements in Cell Therapy Technologies

The landscape of cell therapy is rapidly evolving, driven by advancements in technology and innovative treatment approaches. One significant trend is the focus on CAR-T cell therapy and its expansion into new frontiers. For instance, CAR-T cell therapy has led to sustained remissions in populations of otherwise refractory patients and, more specifically, has demonstrated complete response rates of > 80–97% in certain B-cell malignancies such as acute lymphoblastic leukemia (ALL). Moreover, as of 15 April 2022, there are 2,756 active cell therapy agents in the global immuno-oncology pipeline, compared to 2,031 active agents in the 2021 update. Of the various categories, CAR-T cells continue to lead the cell therapy pipeline and showed 24% growth from last year. Researchers are also exploring the potential of other cell types such as natural killer (NK) cells and tumor-infiltrating lymphocytes (TILs) to enhance the efficacy of cell-based therapies and target a broader spectrum of cancers. For example, NK cells have gained attention as a promising adoptive cell therapy platform for their potential to improve cancer treatments. NK cells offer distinct advantages over T-cells, including major histocompatibility complex class I (MHC-I)-independent tumor recognition and low risk of toxicity, even in an allogeneic setting. Recent data support that the presence of TIL-NK cells is associated with improved overall patient survival in different types of solid tumors such as head and neck, colorectal, breast, and gastric carcinomas.

Gene Editing and the Promise of Next-Generation Therapies

Another transformative trend in the cell therapy market is the integration of gene editing technologies, particularly CRISPR, to engineer cells with enhanced precision and functionality. For instance, CRISPR is already recognized as one of the most significant discoveries in the world of bioscience over the last decade. By precisely modifying the genetic material of cells, scientists aim to correct genetic abnormalities underlying various diseases and develop more effective treatments. This approach holds immense promise for personalized medicine, as it enables the creation of tailor-made therapies that address the specific genetic drivers of an individual’s condition. In fact, personalized medicines have accounted for more than a third of new drug approvals for four of the last five years.

Furthermore, the exploration of allogeneic cell therapies, which utilize cells from a donor rather than the patient themselves, is gaining traction due to its potential for off-the-shelf availability and scalability. As of 15 April 2022, there are 2,756 active cell therapy agents in the global immuno-oncology pipeline, compared to 2,031 active agents in the 2021 update. Of the various categories, CAR-T cells continue to lead the cell therapy pipeline and showed 24% growth from last year. Regardless of the specific modality, development of allogeneic therapies has increased more sharply (33%). As the field continues to advance, the convergence of cutting-edge technologies and innovative treatment strategies heralds a new era of possibilities in the realm of cell-based therapies. For example, there are more than 50 experimental studies underway that use gene editing in people to treat cancer, HIV, blood diseases, and more. This rapid progress underscores the potential of these technologies to revolutionize the future of medicine.

Market Challenges Analysis

Addressing the High Cost Barrier

The high cost of cell therapies presents a significant challenge to their widespread adoption and accessibility. These therapies are prohibitively expensive due to complex manufacturing processes, extensive clinical trials, and personalized treatment approaches. Such costs strain healthcare budgets and limit accessibility for many patients, highlighting the need for innovative strategies to reduce production expenses and ensure equitable access to these life-saving treatments.

Navigating Manufacturing Complexities and Scalability Challenges

Manufacturing cell therapies involves intricate biological processes, making it challenging to ensure consistency, purity, and large-scale production. These complexities impact treatment availability and affordability, posing a barrier to addressing patient needs effectively. Moreover, limited treatment availability and long waiting times further exacerbate the challenge, as production capacity and logistical complexities restrict access to timely therapies. Overcoming these hurdles requires investment in research and development to streamline manufacturing processes and enhance scalability, thereby improving treatment accessibility for patients worldwide.

Market Segmentation Analysis:

By Use Type:

The Cell Therapy Market can be segmented by use type, distinguishing between clinical and research applications. Clinical use encompasses therapies administered to patients for therapeutic purposes, aiming to treat various diseases and medical conditions. These therapies undergo rigorous testing and regulatory approval processes to ensure safety and efficacy before being introduced into clinical practice. On the other hand, research use involves the application of cell therapies in laboratory settings for experimental purposes, such as studying disease mechanisms, drug discovery, and basic research. Research use allows scientists to explore the potential of cell-based treatments, identify new therapeutic targets, and refine existing therapies before advancing to clinical trials. This segmentation facilitates a comprehensive understanding of how cell therapies are utilized across different settings, guiding investment decisions, and strategic planning within the market.

By Therapy Type:

Another crucial segmentation of the Cell Therapy Market is based on therapy type, distinguishing between autologous and allogenic therapies. Autologous therapies involve the use of a patient’s own cells for treatment, minimizing the risk of immune rejection and graft-versus-host disease. These therapies require harvesting and processing the patient’s cells before reintroducing them back into the body. In contrast, allogenic therapies utilize cells from a donor, offering the advantage of off-the-shelf availability and potentially lower production costs. However, allogenic therapies pose challenges related to immune compatibility and the risk of graft rejection, necessitating careful donor selection and immunosuppressive regimens. Understanding this segmentation enables stakeholders to tailor their strategies and offerings to meet the specific needs of both patient populations and optimize market opportunities within each therapy type segment.

Segments:

Based on Use Type:

  • Clinical use
  • Research use

Based on Therapy Type:

  • Autologous Therapies
  • Allogenic Therapies

Based on End User:

  • Hospitals & Clinics
  • Academic & Research Institutes

Based on Technology:

  • Viral Vector Technology
  • Genome Editing Technology
  • Somatic Cell Technology
  • Cell Immortalization Technology
  • Cell Plasticity Technology
  • Three-dimensional Technology

Based on the Geography:

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Regional Analysis

North America

North America currently holds the largest market share, accounting for approximately 40% of the global cell therapy market. The region’s well-established healthcare infrastructure, extensive research and development activities, and the presence of major industry players have contributed to its dominant position. The United States, in particular, has been at the forefront of cell therapy innovations, with significant investments in clinical trials and the development of advanced cell-based treatments for conditions such as cancer, autoimmune disorders, and cardiovascular diseases.

Europe

Europe follows closely behind, with a market share of around 30%. Countries like Germany, the United Kingdom, and France have been proactive in supporting cell therapy research and development, fostering collaborations between academia and industry. The region’s focus on advancing regenerative medicine, the availability of skilled professionals, and the increasing demand for personalized therapies have fueled market growth. Additionally, favorable regulatory frameworks and initiatives aimed at promoting cell therapy development have further boosted the sector’s growth in Europe.

Key Player Analysis

  1. Kolon TissueGene Inc.
  2. JCR Pharmaceuticals Co. Ltd
  3. Castle Creek Biosciences Inc.
  4. Anterogen Co. Ltd
  5. The Future of Biotechnology
  6. Celgene Corporation
  7. Tameika Cell Technologies Inc.
  8. Cells for Cells
  9. MEDIPOST
  10. NuVasive Inc.

Competitive Analysis

In the highly competitive Cell Therapy Market, several leading players are vying for market share and dominance. Celgene Corporation stands out as a major player, leveraging its extensive experience in biotechnology and strong research and development capabilities to develop innovative cell therapies. Kolon TissueGene Inc. and Anterogen Co. Ltd. are notable competitors, focusing on advanced tissue engineering technologies and pioneering treatments for various medical conditions. JCR Pharmaceuticals Co. Ltd. and MEDIPOST bring unique expertise in regenerative medicine and stem cell therapy, positioning themselves as key contenders in the market. Castle Creek Biosciences Inc. and NuVasive Inc. are also formidable competitors, specializing in novel approaches to cell-based treatments and orthopedic applications, respectively. Additionally, emerging players like Tameika Cell Technologies Inc. and Cells for Cells are gaining traction with their focus on niche markets and cutting-edge cell therapy solutions. As the industry continues to evolve, intense competition and strategic partnerships will drive innovation and shape the landscape of the Cell Therapy Market.

Recent Developments

In 2022, Miracell, a Korean stem cell therapy company, expanded its market presence by entering the Middle East market in March, following its success in Europe. The company’s CEO reported that afternoons were fully occupied with teleconferences with potential Middle Eastern buyers, highlighting the keen interest in Miracell’s offerings. Established in 2009, Miracell specializes in stem cell therapy and cell banking, positioning itself as a leader in regenerative medicine.

In January 2022, KIMMTRAK Immunocore achieved a significant milestone as its treatment for advanced and metastatic uveal melanoma received approval from the FDA. This approval underscores the effectiveness and potential of KIMMTRAK Immunocore’s treatment in addressing a challenging medical condition, providing hope for patients and healthcare providers alike.

In February 2022, Thermo Fisher Scientific introduced comprehensive and integrated commercial packaging and distribution services aimed at facilitating the transition from clinic to commercial release for patients across the U.S. and Europe. Known as Patheon Commercial Packaging Services, this new end-to-end solution combines worldwide distribution and serialization to support programmers in optimizing their logistics strategy, further enhancing patient access to vital treatments.

Market Concentration & Characteristics

In the Cell Therapy Market, market concentration is influenced by several factors, including the presence of key players with significant market share and the level of competition within the industry. The market exhibits characteristics of both consolidation and diversification, with a few major companies dominating the landscape while numerous smaller firms contribute to innovation and niche offerings. Key characteristics include the presence of established pharmaceutical giants like Celgene Corporation and emerging biotechnology startups focusing on novel cell-based treatments. Market concentration also reflects the complexity of regulatory requirements and the high barriers to entry due to the rigorous testing and approval processes involved in bringing cell therapies to market. Additionally, strategic partnerships, mergers, and acquisitions play a pivotal role in shaping the competitive dynamics of the market, further influencing its concentration and characteristics. As the market continues to evolve, maintaining a balance between consolidation and diversity will be essential for fostering innovation and ensuring accessibility to transformative cell therapies.

Report Coverage

The research report offers an in-depth analysis based on Use Type, Therapy Type, End User, Technology, and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Future Outlook

  1. Continued Growth: The Cell Therapy Market is poised for significant expansion, driven by increasing demand for innovative treatment options and advancements in biotechnology.
  2. Diversification of Applications: Cell therapies are expected to extend beyond oncology to address a wider range of diseases, including autoimmune disorders, neurological conditions, and cardiovascular diseases.
  3. Personalized Medicine: There will be a growing emphasis on personalized cell therapies, tailoring treatments to individual patients based on their genetic makeup and disease characteristics.
  4. Regulatory Advancements: Regulatory agencies will continue to refine guidelines and approval processes to ensure the safety and efficacy of cell therapies while facilitating timely market access.
  5. Technological Innovations: Ongoing developments in gene editing, stem cell engineering, and manufacturing processes will drive the development of more advanced and cost-effective cell therapies.
  6. Market Consolidation: The market may witness consolidation as larger pharmaceutical companies acquire smaller biotech firms to expand their cell therapy portfolios and market presence.
  7. Global Expansion: Cell therapy companies will increasingly target emerging markets and regions with growing healthcare infrastructure to capitalize on untapped opportunities.
  8. Enhanced Access and Affordability: Efforts to streamline manufacturing processes and optimize distribution channels will improve accessibility and affordability of cell therapies for patients worldwide.
  9. Collaboration and Partnerships: Collaborative efforts between industry players, academic institutions, and healthcare providers will foster innovation and accelerate the development and commercialization of cell therapies.
  10. Patient-Centric Focus: There will be a heightened focus on addressing patient needs and preferences, ensuring that cell therapies are accessible, affordable, and aligned with patient-centered care models.

1. Introduction
1.1 Report Description
1.2 Purpose of the Report
1.3 USP & Key Offerings
1.4 Key Benefits for Stakeholders
1.5 Target Audience
1.6 Report Scope
1.7 Regional Scope
2. Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3. Executive Summary
4. Introduction
4.1 Overview
4.2 Key Industry Trends
5. Cell Therapy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6. Market Breakup by Use Type
6.1 Clinical Use
6.1.1 Market Trends
6.1.2 Market Forecast
6.1.3 Revenue Share
6.1.4 Revenue Growth Opportunity
6.2 Research Use
6.2.1 Market Trends
6.2.2 Market Forecast
6.2.3 Revenue Share
6.2.4 Revenue Growth Opportunity
7. Market Breakup by Therapy Type
7.1 Online
7.1.1 Market Trends
7.1.2 Market Forecast
7.1.3 Revenue Share
7.1.4 Revenue Growth Opportunity
7.2 Offline
7.2.1 Market Trends
7.2.2 Market Forecast
7.2.3 Revenue Share
7.2.4 Revenue Growth Opportunity
8. Market Breakup by End User
8.1 Hospitals & Clinics
8.1.1 Market Trends
8.1.2 Market Forecast
8.1.3 Revenue Share
8.1.4 Revenue Growth Opportunity
8.2 Academic & Research Institutes
8.2.1 Market Trends
8.2.2 Market Forecast
8.2.3 Revenue Share
8.2.4 Revenue Growth Opportunity
9. Market Breakup by Technology
9.1 Viral Vector Technology
9.1.1 Market Trends
9.1.2 Market Forecast
9.1.3 Revenue Share
9.1.4 Revenue Growth Opportunity
9.2 Genome Editing Technology
9.2.1 Market Trends
9.2.2 Market Forecast
9.2.3 Revenue Share
9.2.4 Revenue Growth Opportunity
9.3 Somatic Cell Technology
9.3.1 Market Trends
9.3.2 Market Forecast
9.3.3 Revenue Share
9.3.4 Revenue Growth Opportunity
9.4 Cell Immortalization Technology
9.4.1 Market Trends
9.4.2 Market Forecast
9.4.3 Revenue Share
9.4.4 Revenue Growth Opportunity
9.5 Cell Plasticity Technology
9.5.1 Market Trends
9.5.2 Market Forecast
9.5.3 Revenue Share
9.5.4 Revenue Growth Opportunity
9.6 Three-dimensional Technology
9.6.1 Market Trends
9.6.2 Market Forecast
9.6.3 Revenue Share
9.6.4 Revenue Growth Opportunity
10. Market Breakup by Region
10.1. North America
10.1.1. United States
10.1.1.1. Market Trends
10.1.1.2. Market Forecast
10.1.2. Canada
10.1.2.1. Market Trends
10.1.2.2. Market Forecast
10.2. Asia-Pacific
10.2.1. China
10.2.2. Japan
10.2.3. India
10.2.4. South Korea
10.2.5. Australia
10.2.6. Indonesia
10.2.7. Others
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. United Kingdom
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Others
10.4. Latin America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Others
10.5. Middle East and Africa
10.5.1. Market Trends
10.5.2. Market Breakup by Country
10.5.3. Market Forecast
11. SWOT Analysis
11.1. Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
12. Value Chain Analysis
13. Porters Five Forces Analysis
13.1. Overview
13.2. Bargaining Power of Buyers
13.3. Bargaining Power of Suppliers
13.4. Degree of Competition
13.5. Threat of New Entrants
13.6. Threat of Substitutes
14. Price Analysis
15. Competitive Landscape
15.1. Market Structure
15.2. Key Players
15.3. Profiles of Key Players
15.3.1. Kolon TissueGene Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. Financials
15.3.1.4. SWOT Analysis
15.3.2. JCR Pharmaceuticals Co. Ltd
15.3.3. Castle Creek Biosciences Inc.
15.3.4. Anterogen Co. Ltd
15.3.5. The Future of Biotechnology
15.3.6. Celgene Corporation
15.3.7. Tameika Cell Technologies Inc.
15.3.8. Cells for Cells
15.3.9. MEDIPOST
15.3.10. NuVasive Inc.
16. Research Methodology

Frequently Asked Questions:

What is the current size of the Cell Therapy Market?

The Cell Therapy Market is projected to grow from USD 5291.58 million in 2024.

What factors are driving the growth of the Cell Therapy Market?

Key factors include increasing prevalence of chronic diseases such as cancer and autoimmune disorders, advancements in biotechnology and genetic engineering, favorable regulatory landscapes, and the rising adoption of personalized medicine.

What are the key segments within the Cell Therapy Market?

The key segments within the market are based on use type (clinical use, research use), therapy type (autologous therapies, allogenic therapies), and technology (viral vector technology, genome editing technology, etc.)

What are some challenges faced by the Cell Therapy Market?

Major challenges include the high cost of therapies, complexities in manufacturing and scalability, and navigating stringent regulatory environments.

Who are the major players in the Cell Therapy Market?

Major players include Kolon TissueGene Inc., JCR Pharmaceuticals Co. Ltd, Castle Creek Biosciences Inc., Anterogen Co. Ltd, and Celgene Corporation, among others.

Small Animal Respiratory Diseases Treatment Market

Published:
Report ID: 10022

AI in Vitro Diagnostics Market

Published:
Report ID: 39163

U.S. 503b Compounding Pharmacies Market

Published:
Report ID: 15988

UAE Minimally Invasive Biopsy Techniques Market

Published:
Report ID: 38790

Saudi Arabia Minimally Invasive Biopsy Technique Market

Published:
Report ID: 38766

Lung Cancer Therapeutics Market

Published:
Report ID: 38769

Breast Cancer Market

Published:
Report ID: 38761

Positive Patient Identification (PPID) Market

Published:
Report ID: 10622

Inflation Devices Market

Published:
Report ID: 38697

Microbiology Culture Market

Published:
Report ID: 38672

Medical Processing Seals Market

Published:
Report ID: 38667

Egypt In-Vitro Fertilization (IVF) Market

Published:
Report ID: 38526

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN